{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:46:23Z","timestamp":1786988783515,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373493"],"award-info":[{"award-number":["81373493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science Foundation of China","doi-asserted-by":"publisher","award":["12JJ6083"],"award-info":[{"award-number":["12JJ6083"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.eplepsyres.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T22:54:55Z","timestamp":1442012095000},"page":"52-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy"],"prefix":"10.1016","volume":"117","author":[{"given":"Ping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Hao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00007691-198409000-00001","article-title":"Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children","volume":"6","author":"Bourgeois","year":"1984","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1059-1311(97)80001-5","article-title":"Established antiepileptic drugs","volume":"6","author":"Brodie","year":"1997","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0015","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2217\/pgs.11.103","article-title":"Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients","volume":"12","author":"Chen","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0020","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.nrl.0000340792.61037.40","article-title":"Antiepileptic drug interactions","volume":"14","author":"Diaz","year":"2008","journal-title":"Neurologist"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biosystems.2003.10.001","article-title":"The relationship between synonymous codon usage and protein structure in Escherichia coli and Homo sapiens","volume":"73","author":"Gu","year":"2004","journal-title":"Biosystems"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00007691-200306000-00021","article-title":"How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10,11-epoxide in serum samples?","volume":"25","author":"Hermida","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1124\/dmd.104.001313","article-title":"Evidence of significant contribution from CYP3A5 to hepatic drug metabolism","volume":"32","author":"Huang","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2710.2004.00557.x","article-title":"Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data","volume":"29","author":"Jiao","year":"2004","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0055","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00008571-200406000-00007","article-title":"Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms","volume":"14","author":"Meissner","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","article-title":"Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy","volume":"21","author":"Meng","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0070","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2217\/pgs.11.33","article-title":"Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients","volume":"12","author":"Miura","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0075","doi-asserted-by":"crossref","first-page":"502","DOI":"10.18433\/J3Q888","article-title":"Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients","volume":"16","author":"Panomvana","year":"2013","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2710.2009.01057.x","article-title":"Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients","volume":"34","author":"Park","year":"2009","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0095","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/14622416.7.4.551","article-title":"ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients","volume":"7","author":"Seo","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0009-9120(01)00186-2","article-title":"Characterization of cross reactivity by carbamazepine 10,11-epoxide with carbamazepine assays","volume":"34","author":"Shen","year":"2001","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0105","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1248\/bpb.19.1090","article-title":"The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs","volume":"19","author":"Shinoda","year":"1996","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00007691-199506000-00002","article-title":"Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase?","volume":"17","author":"Svinarov","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0115","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199612000-00006","article-title":"Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication","volume":"18","author":"Svinarov","year":"1996","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1528-1167.2011.03121.x","article-title":"Standards for epidemiologic studies and surveillance of epilepsy","volume":"52","author":"Thurman","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/2000-1967-225","article-title":"Relative proportions of serum carbamazepine and its pharmacologically active 10,11-epoxy derivative: effect of polytherapy and renal insufficiency","volume":"113","author":"Tutor-Crespo","year":"2008","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0130","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1212\/01.WNL.0000059867.35547.DE","article-title":"The prevalence and treatment gap in epilepsy in China: an ILAE\/IBE\/WHO study","volume":"60","author":"Wang","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0135","first-page":"166","article-title":"Clinical significance of some genetic polymorphisms of cytochrome P-450 subfamilies CYP2D CYP2E and CYP3A \u2013 Part II","volume":"27","author":"Wojtczak A","year":"2009","journal-title":"Pol. Merkur. Lek."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eplepsyres.2013.09.011","article-title":"Effects of EPHX1 SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy","volume":"107","author":"Yun","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0145","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00228-009-0726-4","article-title":"CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients","volume":"66","author":"Zhang","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2015.09.001_bib0155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1755-5949.2012.00321.x","article-title":"Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up","volume":"18","author":"Zhou","year":"2012","journal-title":"CNS Neurosci. Ther."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115300437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115300437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:33:57Z","timestamp":1760276037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121115300437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":31,"alternative-id":["S0920121115300437"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.09.001","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}